Journal article icon

Journal article

Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial

Abstract:

Background Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02 (galactoarabino-rhamnogalaturonate) has been shown to reduce hepatic fibrosis in animal studies, and lower serum biomarkers of NASH fibrogenesis in humans. The primary aim of this study was to determine the difference between four-months of treatment with GR-MD-02 or placebo in liver inflammation and fibrosis as measured by iro...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1371/journal.pone.0203054

Authors


More by this author
Role:
Author
ORCID:
0000-0002-0152-6528
Publisher:
Public Library of Science
Journal:
PLoS ONE More from this journal
Volume:
13
Issue:
9
Article number:
e0203054
Publication date:
2018-09-07
Acceptance date:
2018-08-12
DOI:
EISSN:
1932-6203
Pmid:
30192782
Language:
English
Pubs id:
pubs:920337
UUID:
uuid:073a000d-1de3-490b-9f40-cdc5490eceb4
Local pid:
pubs:920337
Source identifiers:
920337
Deposit date:
2019-02-14

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP